Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + AC-T in High-risk TNBC
NCT07622836Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in triple-negative breast cancer (TNBC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Disease-Free Survival at 3 years. Started Jun 2026; status: recruiting.
02
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07622836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622836.